Pharmacovigilance in a genomic era

Abstract

In summary, the application of pharmacogenomics in postmarketing surveillance systems requires integrated action involving a variety of groups. Policy frameworks from regulatory bodies need to be developed; investment and funding of research from government and the private sector need to be enhanced; networking and communications between different disciplines need to be continued; an integrated surveillance system needs to be established; education for the public, health care providers, and researchers needs to be improved; practice guidelines and recommendations relating to pharmacogenomics research should be developed. Success in this field will require a prudent and scientific approach, with the avoidance of hype. © 2006 Nature Publishing Group. All rights reserved.